Ascentage Pharma Reports Significant Revenue Growth in 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy AAPG?
Source: Newsfilter
- Revenue Growth: In 2025, Ascentage Pharma's product sales and commercial rights revenues surged by 90% year-over-year to $82.1 million (RMB 574.1 million), indicating strong market performance and growth potential for the company.
- Strong Sales of Olverembatinib: Sales of Olverembatinib increased by 81% year-over-year to $62.2 million (RMB 435.3 million), reflecting the drug's growing acceptance and demand in the Chinese market, thereby enhancing the company's market position.
- Lisaftoclax Market Performance: Since its launch in July 2025, Lisaftoclax generated $10.1 million (RMB 70.6 million) in sales over five months, demonstrating strong market acceptance and potential growth opportunities for the new product.
- Clinical Trial Progress: The company is currently conducting nine registrational Phase III clinical trials globally, with four cleared by the FDA and EMA, showcasing Ascentage Pharma's ongoing commitment to innovative drug development and strategic positioning.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AAPG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AAPG
Wall Street analysts forecast AAPG stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 23.150
Low
45.00
Averages
48.67
High
51.00
Current: 23.150
Low
45.00
Averages
48.67
High
51.00
About AAPG
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ascentage Pharma Reports Significant Revenue Growth in 2025 Financial Results
- Revenue Growth: In 2025, Ascentage Pharma's product sales and commercial rights revenues surged by 90% year-over-year to $82.1 million (RMB 574.1 million), indicating strong market performance and growth potential for the company.
- Strong Sales of Olverembatinib: Sales of Olverembatinib increased by 81% year-over-year to $62.2 million (RMB 435.3 million), reflecting the drug's growing acceptance and demand in the Chinese market, thereby enhancing the company's market position.
- Lisaftoclax Market Performance: Since its launch in July 2025, Lisaftoclax generated $10.1 million (RMB 70.6 million) in sales over five months, demonstrating strong market acceptance and potential growth opportunities for the new product.
- Clinical Trial Progress: The company is currently conducting nine registrational Phase III clinical trials globally, with four cleared by the FDA and EMA, showcasing Ascentage Pharma's ongoing commitment to innovative drug development and strategic positioning.
See More
Monte Rosa Therapeutics Shares Surge 45.2% After Phase 1 Data Release
- Stock Surge: Monte Rosa Therapeutics Inc (NASDAQ:GLUE) shares soared 45.2% to $23.25 after announcing interim data from its Phase 1 clinical study evaluating MRT-8102, indicating strong market confidence in its research progress and potentially attracting more investor interest.
- Acquisition Rumors: Ventyx Biosciences Inc (NASDAQ:VTYX) saw a 37.5% increase to $13.82 following reports that Eli Lilly & Co (NYSE:LLY) is in advanced talks to acquire the company for over $1 billion, which may further drive market interest in biotech stocks.
- Analyst Rating: Erasca Inc (NASDAQ:ERAS) rose 17.1% to $4.25 after Piper Sandler analyst Kelsey Goodwin initiated coverage with an Overweight rating and a price target of $5, reflecting optimism about its future growth potential.
- Market Dynamics: The overall market was mixed, with the Dow Jones index falling around 0.2%, yet several biotech stocks performed strongly, reflecting ongoing investor interest and confidence in the sector, which may signal future investment opportunities.
See More
Novo Nordisk Receives FDA Approval for Wegovy, Shares Surge 8.6%
- FDA Approval: Novo Nordisk's GLP-1 drug Wegovy received FDA approval, marking the first of its kind globally, which signifies a major breakthrough for the company in the weight loss medication market and is expected to drive sales growth and enhance competitive positioning.
- Stock Surge: Following the approval news, Novo Nordisk's shares rose 8.6% to $52.26, reflecting strong investor confidence in the potential market demand for the new drug, which may enhance the company's market capitalization and investment appeal.
- Market Reaction: Other related companies like WW International and Lifezone Metals also saw gains due to positive market sentiment, with WW International's stock jumping 14.4%, indicating increased investor interest in health and weight loss-related products, potentially boosting overall industry growth.
- Industry Impact: Novo Nordisk's successful approval may prompt other pharmaceutical companies to accelerate the development of similar products, thereby driving competition in the GLP-1 market and fostering innovation and market expansion.
See More
Cementos Pacasmayo, Rezolve AI, Emerald Holding, and Other Major Stocks Rising on Monday
U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones index dropping over 100 points on Tuesday.
Cementos Pacasmayo Surge: Shares of Cementos Pacasmayo SAA rose 47.4% to $10.30 after Holcim agreed to purchase a majority stake in its parent company.
Notable Stock Gains: Several companies saw significant stock increases, including Rezolve AI PLC (23.7%), Emerald Holding Inc (17%), and Tilray Brands Inc (15%).
Strategic Moves and Buybacks: Sezzle Inc announced a $100 million stock buyback, while Emerald Holding is reviewing strategic options following acquisition inquiries.
See More
Ascentage Pharma Reports Strong Efficacy of Olverembatinib in CML Treatment
- Efficacy Data Update: Olverembatinib achieved a complete cytogenetic response rate of 76.7% in chronic-phase CML patients, demonstrating its strong potential as a second-line treatment, which may facilitate its advancement to earlier treatment lines.
- Deepening Molecular Responses: With extended treatment duration, the major molecular response rate reached 60% at 21 cycles, indicating that patient responses deepen over time, enhancing its clinical application prospects.
- Consistent Safety Profile: The safety data for Olverembatinib remained consistent with previously reported results, with no new safety signals, ensuring its acceptability and safety for patient use.
- Ongoing Global Registrational Studies: Ascentage Pharma is conducting three global registrational Phase III studies to evaluate Olverembatinib across multiple indications, showcasing the company's commitment to addressing unmet medical needs worldwide.
See More
Ascentage Pharma Presents 66% Efficacy of Olverembatinib at ASH Conference
- Clinical Trial Results: At the ASH Annual Meeting, Ascentage Pharma showcased data from its new drug Olverembatinib combined with low-intensity chemotherapy, revealing a best minimal residual disease (MRD) negativity rate of 66.0% in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients, indicating the drug's potential in treatment.
- Safety Analysis: The combination of Olverembatinib and low-intensity chemotherapy demonstrated a favorable safety profile, with common grade 3 or higher adverse events including neutropenia (63.6%) and thrombocytopenia (56.4%), suggesting its acceptability in clinical applications.
- Global Registration Progress: The POLARIS-1 study of Olverembatinib has received clearance from the FDA and EMA, marking a significant milestone in the global development of the drug and potentially offering new treatment options for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
- Market Potential: Ascentage Pharma has signed an exclusive option agreement with Takeda, which, if exercised, would grant Takeda global rights to develop and commercialize Olverembatinib outside of mainland China, Hong Kong, Macau, and Taiwan, thereby expanding its market influence.
See More
Ascentage Pharma Reports Significant Revenue Growth in 2025 Financial Results
- Revenue Growth: In 2025, Ascentage Pharma's product sales and commercial rights revenues surged by 90% year-over-year to $82.1 million (RMB 574.1 million), indicating strong market performance and growth potential for the company.
- Strong Sales of Olverembatinib: Sales of Olverembatinib increased by 81% year-over-year to $62.2 million (RMB 435.3 million), reflecting the drug's growing acceptance and demand in the Chinese market, thereby enhancing the company's market position.
- Lisaftoclax Market Performance: Since its launch in July 2025, Lisaftoclax generated $10.1 million (RMB 70.6 million) in sales over five months, demonstrating strong market acceptance and potential growth opportunities for the new product.
- Clinical Trial Progress: The company is currently conducting nine registrational Phase III clinical trials globally, with four cleared by the FDA and EMA, showcasing Ascentage Pharma's ongoing commitment to innovative drug development and strategic positioning.
See More
Monte Rosa Therapeutics Shares Surge 45.2% After Phase 1 Data Release
- Stock Surge: Monte Rosa Therapeutics Inc (NASDAQ:GLUE) shares soared 45.2% to $23.25 after announcing interim data from its Phase 1 clinical study evaluating MRT-8102, indicating strong market confidence in its research progress and potentially attracting more investor interest.
- Acquisition Rumors: Ventyx Biosciences Inc (NASDAQ:VTYX) saw a 37.5% increase to $13.82 following reports that Eli Lilly & Co (NYSE:LLY) is in advanced talks to acquire the company for over $1 billion, which may further drive market interest in biotech stocks.
- Analyst Rating: Erasca Inc (NASDAQ:ERAS) rose 17.1% to $4.25 after Piper Sandler analyst Kelsey Goodwin initiated coverage with an Overweight rating and a price target of $5, reflecting optimism about its future growth potential.
- Market Dynamics: The overall market was mixed, with the Dow Jones index falling around 0.2%, yet several biotech stocks performed strongly, reflecting ongoing investor interest and confidence in the sector, which may signal future investment opportunities.
See More
Novo Nordisk Receives FDA Approval for Wegovy, Shares Surge 8.6%
- FDA Approval: Novo Nordisk's GLP-1 drug Wegovy received FDA approval, marking the first of its kind globally, which signifies a major breakthrough for the company in the weight loss medication market and is expected to drive sales growth and enhance competitive positioning.
- Stock Surge: Following the approval news, Novo Nordisk's shares rose 8.6% to $52.26, reflecting strong investor confidence in the potential market demand for the new drug, which may enhance the company's market capitalization and investment appeal.
- Market Reaction: Other related companies like WW International and Lifezone Metals also saw gains due to positive market sentiment, with WW International's stock jumping 14.4%, indicating increased investor interest in health and weight loss-related products, potentially boosting overall industry growth.
- Industry Impact: Novo Nordisk's successful approval may prompt other pharmaceutical companies to accelerate the development of similar products, thereby driving competition in the GLP-1 market and fostering innovation and market expansion.
See More
Cementos Pacasmayo, Rezolve AI, Emerald Holding, and Other Major Stocks Rising on Monday
U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones index dropping over 100 points on Tuesday.
Cementos Pacasmayo Surge: Shares of Cementos Pacasmayo SAA rose 47.4% to $10.30 after Holcim agreed to purchase a majority stake in its parent company.
Notable Stock Gains: Several companies saw significant stock increases, including Rezolve AI PLC (23.7%), Emerald Holding Inc (17%), and Tilray Brands Inc (15%).
Strategic Moves and Buybacks: Sezzle Inc announced a $100 million stock buyback, while Emerald Holding is reviewing strategic options following acquisition inquiries.
See More
Ascentage Pharma Reports Strong Efficacy of Olverembatinib in CML Treatment
- Efficacy Data Update: Olverembatinib achieved a complete cytogenetic response rate of 76.7% in chronic-phase CML patients, demonstrating its strong potential as a second-line treatment, which may facilitate its advancement to earlier treatment lines.
- Deepening Molecular Responses: With extended treatment duration, the major molecular response rate reached 60% at 21 cycles, indicating that patient responses deepen over time, enhancing its clinical application prospects.
- Consistent Safety Profile: The safety data for Olverembatinib remained consistent with previously reported results, with no new safety signals, ensuring its acceptability and safety for patient use.
- Ongoing Global Registrational Studies: Ascentage Pharma is conducting three global registrational Phase III studies to evaluate Olverembatinib across multiple indications, showcasing the company's commitment to addressing unmet medical needs worldwide.
See More
Ascentage Pharma Presents 66% Efficacy of Olverembatinib at ASH Conference
- Clinical Trial Results: At the ASH Annual Meeting, Ascentage Pharma showcased data from its new drug Olverembatinib combined with low-intensity chemotherapy, revealing a best minimal residual disease (MRD) negativity rate of 66.0% in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients, indicating the drug's potential in treatment.
- Safety Analysis: The combination of Olverembatinib and low-intensity chemotherapy demonstrated a favorable safety profile, with common grade 3 or higher adverse events including neutropenia (63.6%) and thrombocytopenia (56.4%), suggesting its acceptability in clinical applications.
- Global Registration Progress: The POLARIS-1 study of Olverembatinib has received clearance from the FDA and EMA, marking a significant milestone in the global development of the drug and potentially offering new treatment options for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
- Market Potential: Ascentage Pharma has signed an exclusive option agreement with Takeda, which, if exercised, would grant Takeda global rights to develop and commercialize Olverembatinib outside of mainland China, Hong Kong, Macau, and Taiwan, thereby expanding its market influence.
See More
